12,372 trials
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment — -0.054; 0.131; 0.152; 0.119 Liter — p=<0.0001
Alzheimer's Disease · Agitation
Primary: NeuroBehavior Rating Scale-- Agitation — 4.33; 5.26 units on a scale — p=0.036
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment — -0.022; 0.150; 0.152; 0.136 Liter — p=<0.0001
Postpartum Hemorrhage
Primary: Intraoperative Blood Loss — 357.8; 641.7; 457.5 millilitres
Malaria, Falciparum
Primary: Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitologic Response (ACPR) at Day 28 in the Modified Intent-to-treat…
Parkinson's Disease
Primary: Change From Baseline in Mean Total Daily OFF Time Using Parkinson's Disease Patient Diary — -0.76; -1.25 hours — p=0.0228
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Recurrence-Free Survival of Eligible Patients Who Received a Random Treatment Allocation. — 159; 175; 111; 107 participants
Attention Deficit Hyperactivity Disorder
Primary: Swanson, Kotin, Agler, M-Flynn, and Pelham Rating Scale (SKAMP)-Combined Scores at Hour 4 Post-Dose — 7.1; 19.3 units on a scale — p=<0.0001
Osteoarthritis of the Knee · Coagulopathy
Primary: Change From Baseline to Week 4 in Laboratory Results of Prothrombin Time (PT) — 6.97; 0.96; -0.04 seconds
Lymphoma
Primary: Treatment Failure - Percentage of Participants With an Event — 68; 67 percentage of participants
Therapeutic Treatment of Inhalation Anthrax
Primary: Number of Participants Who Developed a Positive Anti-raxibacumab Antibody Response — 0 Participants
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) — 1.040; 1.191; 1.256 Liters — p=<0.001
Infantile Hemangioma
Primary: Interim Analysis : Complete/Nearly Complete Resolution of the Target Infantile Hemangioma at Week 24 Compared to Baseline Based on the Intra-patient Blinded Centralized…
Infection, Human Immunodeficiency Virus I
Primary: Percentage of Participants With Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] <50 Copies (c)/Milliliter (mL) Through Week 48 — 88; 85…
Cystic Fibrosis
Primary: Change From Baseline to End of the Treatment Period of Forced Expiratory Volume in 1 Second (FEV1), Expressed as Percentage of Predicted Normal — 6.99; 7.51 percentage…